Search

Meeting Coverage:

Association for Research in Vision & Ophthalmology

ARVO: 2024

Gene Therapy for Wet AMD: Pharmacodynamic Changes

Ramanath Bhandari, MD

Show Description +

Ramanath Bhandari, MD, explains changes in the manufacturing process for the investigational ABBV-RGX-314 (Abbvie/Regenxbio) for wet AMD.

Posted: 5/20/2024

Keywords:

retina-meeting-recap

•

ABBV-RGX-314

•

AbbVie

•

REGENXBIO

•

Wet AMD

•

Age-Related Macular Degeneration (AMD)

•

pharmacodynamic

Up Next

Faricimab in the Real World: 2 Years of Data

Faricimab in the Real World: 2 Years of Data

Aamir Aziz, MD

Addressing the AMD Epidemic

Addressing the AMD Epidemic

Emily Chew, MD

Managing Concurrent Wet AMD and GA

Managing Concurrent Wet AMD and GA

Ted Leng, MD

A Look at Three-Year Data for Pegcetacoplan

A Look at Three-Year Data for Pegcetacoplan

Ashkan Abbey, MD

The Latest Data on Photobiomodulation

The Latest Data on Photobiomodulation

Todd Schneiderman, MD

A Subretinal Implant for GA: Improving Vision

A Subretinal Implant for GA: Improving Vision

Mahi Muqit, MD

Optogenetics for RP: 12-Month Data

Optogenetics for RP: 12-Month Data

Allen Ho, MD

New Data on Oral DR Therapy

New Data on Oral DR Therapy

Daniel Su, MD

Outcomes with 8 mg Aflibercept: Does Prior DME Treatment Matter?

Outcomes with 8 mg Aflibercept: Does Prior DME Treatment Matter?

Nitish Mehta, MD

Imaging AMD: Microperimetry and OCT

Imaging AMD: Microperimetry and OCT

Giulia Corradetti, MD

SriniVas R. Sadda, MD, Steps in as ARVO President

SriniVas R. Sadda, MD, Steps in as ARVO President

Vas Sadda, MD

Back to All Videos

Gene Therapy for Wet AMD: Pharmacodynamic Changes

Ramanath Bhandari, MD

Ramanath Bhandari, MD, explains changes in the manufacturing process for the investigational ABBV-RGX-314 (Abbvie/Regenxbio) for wet AMD.

Posted: 5/20/2024

Keywords:

retina-meeting-recap

•

ABBV-RGX-314

•

AbbVie

•

REGENXBIO

•

Wet AMD

•

Age-Related Macular Degeneration (AMD)

•

pharmacodynamic

Please log in to leave a comment.

More From ARVO: 2024 Coverage

Optogenetics for RP: 12-Month Data

Optogenetics for RP: 12-Month Data

Allen Ho, MD

New Data on Oral DR Therapy

New Data on Oral DR Therapy

Daniel Su, MD

Outcomes with 8 mg Aflibercept: Does Prior DME Treatment Matter?

Outcomes with 8 mg Aflibercept: Does Prior DME Treatment Matter?

Nitish Mehta, MD

Imaging AMD: Microperimetry and OCT

Imaging AMD: Microperimetry and OCT

Giulia Corradetti, MD

Bryn Mawr Communications, LLC, and Eyetube.net are not affiliated with the official program of ARVO: 2024.